Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ventyx Biosciences
Biotech
Ventyx's CV drug rapidly reduces cardio risk biomarker
Ventyx Biosciences’ cardiovascular disease drug cut levels of a biomarker for stroke and other serious risks by almost 80% within a week.
James Waldron
Oct 23, 2025 9:45am
Ventyx posts Parkinson's data ahead of potential Sanofi talks
Jun 17, 2025 9:05am
Sanofi makes $27M equity investment in Ventyx
Sep 23, 2024 11:24am
Ventyx's last hope for inflammatory med ends in Crohn's failure
Jul 29, 2024 9:45am
Atai, Eli Lilly, Novartis & more—Chutes & Ladders
May 17, 2024 8:30am
Former FDA leader Woodcock inspires Biotech Sisterhood summit
Apr 24, 2024 9:23am
